advancing innovation to save lives

GHTC honors Sen. Blunt, Rep. Rosa DeLauro & developers of child-friendly TB Medicines

GHTC honored Senator Roy Blunt (R-MO) and Congresswoman Rosa DeLauro (D-CT) at its second annual Innovating for Impact Awards, which celebrates US policymakers and partnerships driving progress in global health innovation. GHTC also recognized the partnership that developed and introduced improved child-friendly tuberculosis (TB) medicines.
Learn More

More than 150 signatories join GHTC in calling for R&D to be included in GHSA

More than 150 organizations and individuals from around the world have already signed on to GHTC's petition calling for the inclusion of an R&D action package in the 2019-2024 Global Health Security Agenda (GHSA) framework.
Take Action

Member Spotlight: DNDi

A patient-needs driven, not-for-profit research and development organization, Drugs for Neglected Diseases initiative (DNDi) works to deliver new treatments for neglected diseases, in particular leishmaniasis, human African trypanosomiasis, Chagas disease, specific filarial infections, paediatric HIV, mycetoma, and hepatitis C. Since its inception in 2003, DNDi has delivered eight treatments, including fexinidazole, the first all-oral treatment for sleeping sickness, two fixed-dose antimalarials (ASAQ and ASMQ), sodium stibogluconate and paromomycin (SSG&PM) combination therapy for visceral leishmaniasis in Africa and a pediatric dosage form of benznidazole for Chagas disease.
Learn More

GHTC works to save and improve lives by encouraging the research and development of essential health technologies. We bring together more than 30 nonprofit organizations, academic institutions, and aligned businesses to advance policies to accelerate the creation of new drugs, vaccines, diagnostics, and other tools that bring healthy lives within reach for all people.

Why we're needed

Health technologies have the potential to save millions of lives. New tools are needed to slow the global threat of diseases, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases, and tackle many other pressing health needs. For diseases and conditions primarily affecting people in the world’s poorest places, there is little to no commercial market to spur R&D. Strong investment and innovative solutions are needed to catalyze the development of new technologies to bring health and opportunity within reach for all people.

Learn more
PATH/Patrick McKern
GHTC sends letter of support for National Biodefense Strategy

GHTC sent a letter to Secretary of Health and Human Services Alex Azar in support of the National Biodefense Strategy released by the Administration in September. The letter commends the goals in the strategy aimed at accelerating basic and applied R&D of new antimicrobials, novel therapeutics, vaccines, and diagnostic tests; promoting increased global capacities for R&D, and integrating R&D into federal planning before and during a potential bio-incident.

PDF
Senator Blunt, Rep. DeLauro, and developers of child-friendly TB medicines honored with GHTC Innovating for Impact Awards

GHTC yesterday honored Senator Roy Blunt (R-MO) and Congresswoman Rosa DeLauro (D-CT) at its second annual Innovating for Impact Awards, which celebrates US policymakers and partnerships driving progress in global health innovation. GHTC also recognized the partnership that developed and introduced improved child-friendly tuberculosis (TB) medicines, making these transformative treatments available to children in need worldwide.

Learn More
View All News & Events

Community Event

PATH/Julie Jacobson
Innovation, Partnership, and Self-Reliance: Health Policy Lessons from India’s Bihar State
Center for Strategic & International Studies
Learn More

Member Event

Policy Cures Research
Launch of the 2018 G-FINDER report
Policy Cures Research
Learn More
View All Events
PATH
Global health research in Maryland: Health is wealth

Maryland is home to two federal health powerhouses, the Food and Drug Administration and the National Institutes of Health (NIH), the world’s largest medical research institute. Together, they employ 25,000 people.

Research!America
Read More
Innovation: The key to fighting HIV/AIDS

Nick Taylor is the program assistant at the GHTC. On Wednesday, he attended a briefing on Capitol Hill hosted by the Office of the Global AIDS Coordinator. Wednesday’s briefing—co-hosted by the Foundation for AIDS Research (amfAR), the President’s Emergency Plan for AIDS Relief (PEPFAR), and the Center for Global Health Policy at the Infectious Diseases Society of America —convened several HIV physicians and scientists to discuss PEPFAR and the evidence-based HIV prevention methods that the program implements in countries with high rates of HIV/AIDS.

GHTC
Read More
View Breakthroughs Blog

Our members work to improve health worldwide